Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate

Yongfeng He, Daniel T. Johnson, Julie S. Yang, Huiqing Wu, Sungyong You, Junhee Yoon, Dong Hoon Lee, Won Kyung Kim, Joseph Aldahl, Vien Le, Erika Hooker, Eun Jeong Yu, Joseph Geradts, Robert Cardiff, Zijie Sun

Research output: Contribution to journalArticle

Abstract

Recent genome analysis of human prostate cancers demonstrated that both AR gene amplification and TP53 mutation are among the most frequently observed alterations in advanced prostate cancer. However, the biological role of these dual genetic alterations in prostate tumorigenesis is largely unknown. In addition, there are no biologically relevant models that can be used to assess the molecular mechanisms for these genetic abnormalities. Here, we report a novel mouse model, in which elevated transgenic AR expression and Trp53 deletion occur simultaneously in mouse prostatic epithelium to mimic human prostate cancer cells. These compound mice developed an earlier onset of high-grade prostatic intraepithelial neoplasia and accelerated prostate tumors in comparison with mice harboring only the AR transgene. Histological analysis showed prostatic sarcomatoid and basaloid carcinomas with massive squamous differentiation in the above compound mice. RNA-sequencing analyses identified a robust enrichment of the signature genes for human prostatic basal cell carcinomas in the above prostate tumors. Master regulator analysis revealed SOX2 as a transcriptional regulator in prostatic basal cell tumors. Elevated expression of SOX2 and its downstream target genes were detected in prostatic tumors of the compound mice. Chromatin immunoprecipitation analyses implicate a coregulatory role of AR and SOX2 in the expression of prostatic basal cell signature genes. Our data demonstrate a critical role of SOX2 in prostate tumorigenesis and provide mechanistic insight into prostate tumor aggressiveness and progression mediated by aberrant AR and p53 signaling pathways.

Original languageEnglish (US)
JournalOncogene
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Androgen Receptors
Prostate
Neoplasms
Prostatic Neoplasms
Carcinogenesis
Prostatic Intraepithelial Neoplasia
Genes
RNA Sequence Analysis
Gene Amplification
Chromatin Immunoprecipitation
Basal Cell Carcinoma
Human Genome
Transgenes
Molecular Biology
Epithelium
Carcinoma
Mutation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate. / He, Yongfeng; Johnson, Daniel T.; Yang, Julie S.; Wu, Huiqing; You, Sungyong; Yoon, Junhee; Lee, Dong Hoon; Kim, Won Kyung; Aldahl, Joseph; Le, Vien; Hooker, Erika; Yu, Eun Jeong; Geradts, Joseph; Cardiff, Robert; Sun, Zijie.

In: Oncogene, 01.01.2019.

Research output: Contribution to journalArticle

He, Y, Johnson, DT, Yang, JS, Wu, H, You, S, Yoon, J, Lee, DH, Kim, WK, Aldahl, J, Le, V, Hooker, E, Yu, EJ, Geradts, J, Cardiff, R & Sun, Z 2019, 'Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate', Oncogene. https://doi.org/10.1038/s41388-019-0901-8
He, Yongfeng ; Johnson, Daniel T. ; Yang, Julie S. ; Wu, Huiqing ; You, Sungyong ; Yoon, Junhee ; Lee, Dong Hoon ; Kim, Won Kyung ; Aldahl, Joseph ; Le, Vien ; Hooker, Erika ; Yu, Eun Jeong ; Geradts, Joseph ; Cardiff, Robert ; Sun, Zijie. / Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate. In: Oncogene. 2019.
@article{81edd70ae63d44acb7f02c70c6955238,
title = "Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate",
abstract = "Recent genome analysis of human prostate cancers demonstrated that both AR gene amplification and TP53 mutation are among the most frequently observed alterations in advanced prostate cancer. However, the biological role of these dual genetic alterations in prostate tumorigenesis is largely unknown. In addition, there are no biologically relevant models that can be used to assess the molecular mechanisms for these genetic abnormalities. Here, we report a novel mouse model, in which elevated transgenic AR expression and Trp53 deletion occur simultaneously in mouse prostatic epithelium to mimic human prostate cancer cells. These compound mice developed an earlier onset of high-grade prostatic intraepithelial neoplasia and accelerated prostate tumors in comparison with mice harboring only the AR transgene. Histological analysis showed prostatic sarcomatoid and basaloid carcinomas with massive squamous differentiation in the above compound mice. RNA-sequencing analyses identified a robust enrichment of the signature genes for human prostatic basal cell carcinomas in the above prostate tumors. Master regulator analysis revealed SOX2 as a transcriptional regulator in prostatic basal cell tumors. Elevated expression of SOX2 and its downstream target genes were detected in prostatic tumors of the compound mice. Chromatin immunoprecipitation analyses implicate a coregulatory role of AR and SOX2 in the expression of prostatic basal cell signature genes. Our data demonstrate a critical role of SOX2 in prostate tumorigenesis and provide mechanistic insight into prostate tumor aggressiveness and progression mediated by aberrant AR and p53 signaling pathways.",
author = "Yongfeng He and Johnson, {Daniel T.} and Yang, {Julie S.} and Huiqing Wu and Sungyong You and Junhee Yoon and Lee, {Dong Hoon} and Kim, {Won Kyung} and Joseph Aldahl and Vien Le and Erika Hooker and Yu, {Eun Jeong} and Joseph Geradts and Robert Cardiff and Zijie Sun",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41388-019-0901-8",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate

AU - He, Yongfeng

AU - Johnson, Daniel T.

AU - Yang, Julie S.

AU - Wu, Huiqing

AU - You, Sungyong

AU - Yoon, Junhee

AU - Lee, Dong Hoon

AU - Kim, Won Kyung

AU - Aldahl, Joseph

AU - Le, Vien

AU - Hooker, Erika

AU - Yu, Eun Jeong

AU - Geradts, Joseph

AU - Cardiff, Robert

AU - Sun, Zijie

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Recent genome analysis of human prostate cancers demonstrated that both AR gene amplification and TP53 mutation are among the most frequently observed alterations in advanced prostate cancer. However, the biological role of these dual genetic alterations in prostate tumorigenesis is largely unknown. In addition, there are no biologically relevant models that can be used to assess the molecular mechanisms for these genetic abnormalities. Here, we report a novel mouse model, in which elevated transgenic AR expression and Trp53 deletion occur simultaneously in mouse prostatic epithelium to mimic human prostate cancer cells. These compound mice developed an earlier onset of high-grade prostatic intraepithelial neoplasia and accelerated prostate tumors in comparison with mice harboring only the AR transgene. Histological analysis showed prostatic sarcomatoid and basaloid carcinomas with massive squamous differentiation in the above compound mice. RNA-sequencing analyses identified a robust enrichment of the signature genes for human prostatic basal cell carcinomas in the above prostate tumors. Master regulator analysis revealed SOX2 as a transcriptional regulator in prostatic basal cell tumors. Elevated expression of SOX2 and its downstream target genes were detected in prostatic tumors of the compound mice. Chromatin immunoprecipitation analyses implicate a coregulatory role of AR and SOX2 in the expression of prostatic basal cell signature genes. Our data demonstrate a critical role of SOX2 in prostate tumorigenesis and provide mechanistic insight into prostate tumor aggressiveness and progression mediated by aberrant AR and p53 signaling pathways.

AB - Recent genome analysis of human prostate cancers demonstrated that both AR gene amplification and TP53 mutation are among the most frequently observed alterations in advanced prostate cancer. However, the biological role of these dual genetic alterations in prostate tumorigenesis is largely unknown. In addition, there are no biologically relevant models that can be used to assess the molecular mechanisms for these genetic abnormalities. Here, we report a novel mouse model, in which elevated transgenic AR expression and Trp53 deletion occur simultaneously in mouse prostatic epithelium to mimic human prostate cancer cells. These compound mice developed an earlier onset of high-grade prostatic intraepithelial neoplasia and accelerated prostate tumors in comparison with mice harboring only the AR transgene. Histological analysis showed prostatic sarcomatoid and basaloid carcinomas with massive squamous differentiation in the above compound mice. RNA-sequencing analyses identified a robust enrichment of the signature genes for human prostatic basal cell carcinomas in the above prostate tumors. Master regulator analysis revealed SOX2 as a transcriptional regulator in prostatic basal cell tumors. Elevated expression of SOX2 and its downstream target genes were detected in prostatic tumors of the compound mice. Chromatin immunoprecipitation analyses implicate a coregulatory role of AR and SOX2 in the expression of prostatic basal cell signature genes. Our data demonstrate a critical role of SOX2 in prostate tumorigenesis and provide mechanistic insight into prostate tumor aggressiveness and progression mediated by aberrant AR and p53 signaling pathways.

UR - http://www.scopus.com/inward/record.url?scp=85069908234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069908234&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-0901-8

DO - 10.1038/s41388-019-0901-8

M3 - Article

C2 - 31358900

AN - SCOPUS:85069908234

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -